Back
Return
Biography
Michael L Goris

Prof. Michael L Goris

School of Medicine

Stanford University, USA

 

Email: mlgoris@stanford.edu

 

Qualifications

1969-1972 Ph.D., Medical Physics, University of California Berkeley, USA

1967-1968 M.S. (Post M.D.), Katholieke Universiteit, Belgium

1963-1967 M.D., Katholieke Universiteit, Belgium

 

Publications (selected)

  1. Malavika Ghosh, Sanjiv Sam Gambhir, Abhijit De, Kent Nowels, Michael Goris, Irene Wapnir: Bioluminescent Monitoring of NIS-mediated131I Ablative Effects in MCF-7 Xenografts. Molecular Imaging 2006, 5: 76-84.
  2. Hilary Hardy Street, Michael L. Goris, George Albert Fisher, Barry W. Wessels, Cheryl Cho3, Carmen Hernandez, Hongyun June Zhu, Yuxia Zhang, Jasvinder Singh Nangiana, Joseph S. Shan, Karen Roberts, Susan J. Knox: Phase I Study of131I-Chimeric(ch) TNT-1/B Monoclonal Antibody for the Treatment of Advanced Colon Cancer. Cancer Biotherapy&Radiopharmaceuticals (2006) 21: 243-256.
  3. Hongyun J. Zhu and Michael L. Goris: Display of myocardial motion by projecting specific components of the 3D motion of myocardial elements on the plane of origin. Nuclear Instruments and Methods in Physics and Research A 569 (2006): 386-388.
  4. Ghosh M,Gambhir SS, De A, Nowels K, Goris M, Wapnir I"Bioluminescent monitoring of NIS-mediated (131)I ablative effects in MCF-7 xenografts."Mol Imaging 2006 Apr-Jun;(5):76-84.
  5. Michael L. Goris, M.D., Ph.D.Hongyun J Zhu, M.D. Terry E Robinson, M.D. A critical discussion of Computer Analysis in Medical Imaging. Proceedings of the thoracic society. 2007; (4): 347-349.
  6. Schipper ML, Goris ML, Gambhir SS, "Evaluation of Herpes Simplex Virus 1 Thymidine Kinase-Mediated Trapping of (131)I FIAU and Prodrug Activation of Ganciclovir as a Synergistic Cancer Radio/Chemotherapy” Mol Imaging Biol (2007) 9:110-116.
  7. Tang XN, Wang Q, Koike MA, Cheng D, Goris ML, Blankenberg FG, Yenari MA, "Monitoring the Protective Effects of Minocycline Treatment with Radiolabeled Annexin V in an Experimental Model of Focal Cerebral Ischemia”, J Nucl Med 2007; (48): 1822-1828.
  8. Corinne Renier, Chen Yao, Michael Goris, Malavika Ghosh, Laurence Katznelson, Kent Nowles, Sanjiv S. Gambhir, Irene Wapnir: Endogenous NIS expr ession and activity in triple negative breast cancers: submitted Annals Surgical Oncology (2009) 16: 962-968.
  9. Iagaru A,Goris ML, Gambhir SS. Perspectives of Molecular Imaging and Radioimmunotherapy in Lymphoma. Radiol Clin North Am. 2008 Mar; 46(2):243-252.
  10. Iagaru A, Goris ML. Rhabdomyosarcoma diffusely metastatic to the bone marrow: suspicious findings on 99mTc-MDP bone scintigraphy confirmed by 18F-18 FDG PET/CT and bone marrow biopsy. Eur J Nucl Med Mol Imaging. 2008 35: 1746.
  11. Iagaru A, Gambhir SS,Goris ML. 90Y-Ibritumomab (Zevalin®) Therapy in Refractory Non-Hodgkin’s Lymphoma: Observations from 111In-Ibritumomab Pre-Treatment Imaging. J Nucl Med. 2008 49: 1809-1812.
  12. Iagaru A, Wang, Y, Mari C, Quon A, Goris ML, Horning S, Gambhir SS. 18F FDG PET/CT Evaluation of Response to Therapy in Lymphoma: When is the Optimal Time for the First Re-evaluation Scan? Hell J Nucl Med 2008 Sep-Dec; 11(3):153-156.
  13. Michael L. Goris, M.D., Ph.D. Terry E. Robinson, M.D.: Sampling density to evaluate quantitative air trapping. Pediatric Radiology 39 (2009), 2221.
  14. Robinson TE, Trapnell BC, Goris ML, Quittell LM, Cornfield DN. Quantitative analysis of longitudinal response to aerosolized granulocayte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolare proteinosus, Chest 2009; 135: 842-848.
  15. Iagaru A, Mittra E, Yaghoubi SS, Dick D, Quon A, Goris ML, Gambhir SS: Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of Malignancy: Results of a pilot=phase study. J Nucl Med 2009 50: 501-505.
  16. John D. Louie, MD, Nishita Kothary, MD, William T. Kuo, MD, Gloria L. Hwang, MD, Lawrence V. Hofmann, MD, Michael L. Goris, MD, Andrei H. Iagaru, MD, and Daniel Y. Sze, MD, PhD: Incorporating Cone-beam CT into the Treatment Planning for Yttrium-90 Radioembolization. J Vasc Interv Radiol 2009; 20: 606–613.
  17. Arutselvan Natarajan1, Gayatri Gowrishankar1, Carsten H. Nielsen1, Sen Wang1, Nicholas Van Bruggen3, Andrei Iagaru1, Michael L.Goris2, Sanjiv S. Gambhir1,2,4*.Evaluation and prediction of human PET imaging dose to monitor NHL therapy using64Cu-DOTA-rituximab and a transgenic mouse model.
  18. Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, Berganos R, Chang E, Liu S, Shen B, Chin FT, Chen X, Gambhir SS "Pilot Pharmacokinetic and Dosimetric Studies of F-FPPRGD2: A PET Radiopharmaceutical Agent for Imaging {alpha}v{beta}3 Integrin Levels."Radiology2011.